Data gathered: November 27
Alternative Data for Biodexa Pharmaceuticals
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | N/A | Sign up | Sign up | Sign up |
| Sentiment | 32 | Sign up | Sign up | Sign up |
| Webpage traffic | 5,000 | Sign up | Sign up | Sign up |
| Google Trends | N/A | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 7 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 11,912 | Sign up | Sign up | Sign up |
| Twitter Followers | 363 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Linkedin Employees | 23 | Sign up | Sign up | Sign up |
About Biodexa Pharmaceuticals
Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of Type 1 diabetes and rare/orphan cancers of the brain.
| Price | $4.93 |
| Target Price | Sign up |
| Volume | 21,860 |
| Market Cap | $2.9M |
| Year Range | $3.59 - $58.25 |
| Dividend Yield | 0% |
| Analyst Rating | 0% buy |
| Industry | Biotechnology |
In the news
 |
Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) Regains Compliance For Continued Listing on NasdaqNovember 11 - Yahoo |
Biodexa Pharmaceuticals Submits SEC Filing with Auditors’ NodOctober 31 - TipRanks |
|
BDRX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Biodexa Pharmaceuticals Plc and Encourages Investors to Contact the FirmOctober 29 - GlobeNewswire |
|
 |
Why Is Brain Cancer-Focused Biodexa Pharmaceuticals Stock Trading Lower On Thursday?October 17 - Biztoc.com |
Biodexa Pharmaceuticals releases patient updates on PFS, OS from MAGIC-1 studyOctober 16 - Thefly.com |
|
Biodexa Pharmaceuticals PLC-ADR trading resumesOctober 15 - Thefly.com |
|
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q2 '24 | 0 | 1.1M | -1.1M | -1.7M | -2.1M | |
| Q1 '24 | 0 | 1.1M | -1.1M | -1.7M | -2.1M | |
| Q4 '23 | 42,000 | 1.1M | -1.1M | -1.8M | -1.1M | |
| Q3 '23 | 42,000 | 1.1M | -1.1M | -1.8M | -1.1M | |
| Q2 '23 | 150,000 | 1.1M | -980,000 | -1.8M | -2.1M |
Insider Transactions View All
No recorded Insider transactions.
Similar companies
Read more about Biodexa Pharmaceuticals (BDRX) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, google trends, 4chan mentions, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter followers, news mentions, customer reviews & linkedin employees.
What is the Market Cap of Biodexa Pharmaceuticals?
The Market Cap of Biodexa Pharmaceuticals is $2.9M.
What is the current stock price of Biodexa Pharmaceuticals?
Currently, the price of one share of Biodexa Pharmaceuticals stock is $4.93.
How can I analyze the BDRX stock price chart for investment decisions?
The BDRX stock price chart above provides a comprehensive visual representation of Biodexa Pharmaceuticals' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Biodexa Pharmaceuticals shares. Our platform offers an up-to-date BDRX stock price chart, along with technical data analysis and alternative data insights.
Does BDRX offer dividends to its shareholders?
As of our latest update, Biodexa Pharmaceuticals (BDRX) does not offer dividends to its shareholders. Investors interested in Biodexa Pharmaceuticals should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of Biodexa Pharmaceuticals?
Some of the similar stocks of Biodexa Pharmaceuticals are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
.